溶质载体超家族50蛋白在乳腺癌中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2022.05.007

Abstract

Abstract: OBJECTIVE: To investigate expression of SLC50A1 and its significance in breast cancers (BC).METHODS: Plasma samples from 39 BC patients who met the inclusion criteria of this study were investigated using the enzyme-linked immunosorbent assay.The Mann-Whitney U-test and Kendall's Tau-b were used to analyze differences and correlations between SLC50A1 protein levels and their clinical data.The multivariate Cox regression was used to investigate prognostic significance of SLC50A1 according to the results of the log-rank test.Furthermore,the TCGA database was downloaded to compared different expressions of SLC50A1 from 1 109 BC and 113 adjacent normal tissues.RESULTS: Clinical data from the BC patients indicated that SLC50A1 protein expression was associated with metastasis,hormone receptor and Ki67(P< 0.05).Correlation analyses of plasma SLC50A1 levels indicated a positive correlation between plasma SLC50A1 level and CA153,Kendall's Tau-b=0.257(P=0.004).Multivariate Cox regression analyses indicated that SLC50A1 was an independent prognostic factor in BC patients (HR=0.385,P=0.03).The TCGA data analyses indicated that the SLC50A1 expression levels were higher in BC than in adjacent tissues (P<0.01).CONCLUSION: Plasma SLC50A1 levels were increased in advanced BC,and SLC50A1 expression was an independent prognostic factor for BC.SLC50A1 may be useful as a target for prognosis prediction and therapy of BC.

Key words: breast cancer, SLC50A1, prognosis, biomarker

CLC Number:

R737.9

ZHANG Haizhi, WEN Xiaofen, HUANG Binliang, LIN Hui, XUE Wenwu, ZENG De, LIN Danxia. Expression and clinical significance of SLC50A1 in breast carcinomas[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 373-377.

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7):783-791.
[3] 张雪,董晓平,管雅喆,等.女性乳腺癌流行病学趋势及危险因素研究进展[J].肿瘤防治研究, 2021, 48(1):87-92.
[4] TARIGHATI E, KEIVAN H, MAHANI H. A review of prognostic and predictive biomarkers in breast cancer[J]. Clin Exp Med, 2022:1-16.
[5] LI G, HU J, HU G H. Biomarker studies in early detection and prognosis of breast cancer[J]. Adv Exp Med Biol, 2017, 1026:27-39.
[6] ŚWITNICKI M P, JUUL M, MADSEN T, et al. PINCAGE:probabilistic integration of cancer genomics data for perturbed gene identification and sample classification[J]. Bioinformatics, 2016, 32(9):1353-1365.
[7] WANG Y, SHU Y, GU C Y, et al. The novel sugar transporter SLC50A1 as a potential serum-based diagnostic and prognostic biomarker for breast cancer[J]. Cancer Manag Res, 2019, 11:865-876.
[8] BUDNY A, STAROSŁAWSKA E, BUDNY B, et al. Epidemiology and diagnosis of breast cancer[J]. Pol Merkur Lekarski, 2019, 46(275):195-204.
[9] LI J X, LIU L Y, FENG Z W, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype:a cohort study[J]. Breast Cancer, 2020, 27(4):621-630.
[10] ZHANG F, DE HAAN-DU J, SIDORENKOV G, et al. Type 2 diabetes mellitus and clinicopathological tumor characteristics in women diagnosed with breast cancer:a systematic review and Meta-analysis[J]. Cancers, 2021, 13(19):4992.
[11] AGRAWAL S, WOZNIAK M, LUC M, et al. Insulin and novel thioglycosides exert suppressive effect on human breast and colon carcinoma cells[J]. Oncotarget, 2017, 8(69):114173-114182.
[12] CHEN L Q, HOU B H, LALONDE S, et al. Sugar transporters for intercellular exchange and nutrition of pathogens[J]. Nature, 2010, 468(7323):527-532.
[13] TAGOH H, KISHI H, MURAGUCHI A. Molecular cloning and characterization of a novel stromal cell-derived cDNA encoding a protein that facilitates gene activation of recombination activating gene (RAG)-1 in human lymphoid progenitors[J]. Biochem Biophys Res Commun, 1996, 221(3):744-749.
[14] VILLAGRÁN M, MUÑOZ M, INOSTROZA E, et al. GLUT1 and GLUT8 support lactose synthesis in Golgi of murine mammary epithelial cells[J]. J Physiol Biochem, 2019, 75(2):209-215.
[15] LIMA-OLIVEIRA G, MONNERET D, GUERBER F, et al. Sample management for clinical biochemistry assays:are serum and plasma interchangeable specimens?[J]. Crit Rev Clin Lab Sci, 2018, 55(7):480-500.
[16] JAROS J A J, GUEST P C, BAHN S, et al. Affinity depletion of plasma and serum for mass spectrometry-based proteome analysis[J]. Methods Mol Biol Clifton N J, 2013, 1002:1-11.
[17] WANG R P, HAN Y, ZHAO Z X, et al. Link synthetic lethality to drug sensitivity of cancer cells[J]. Brief Bioinform, 2017, 20(4):1295-1307.
[18] ZHANG D S, LI J, WANG F Z, et al. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy[J]. Cancer Lett, 2014, 355(2):176-183.
[19] FAN T J, SUN G H, SUN X D, et al. Tumor energy metabolism and potential of 3-bromopyruvate as an inhibitor of aerobic glycolysis:implications in tumor treatment[J]. Cancers, 2019, 11(3):317.

Expression and clinical significance of SLC50A1 in breast carcinomas

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YU Yunliang, WANG Lili, LI Ting, FENG Jiankai. Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 353-360,365.
[2]	WANG Ting, ZHANG Wenwen, ZHANG Yongxin, ZENG Yong, WANG Junling, LI Chengyun. A case-control study on expression of miR-101 cluster and risk of esophageal carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 273-278.
[3]	ZHANG Yuling, LIU Ditian, CHEN Chunfa. Impact of CD68 macrophage infiltration on prognosis in primary small cell esophageal carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 279-283.
[4]	WANG Xujuan, LUO Yongxin, LI Chenqiang, WANG Rujin, ZHENG Tingting. Predictive values of preoperative laboratory indices dNLR, SII and CRP/ALB on recurrences and metastases in breast cancer patient [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 284-288,323.
[5]	FAN Xiaojie, LI Qingjing, GU Lina, SANG Meixiang, SHAN Baoen. Expression of melanoma-associated antigen A gene family in breast cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(3): 184-191.
[6]	XIN Yumeng, LIANG Huanxi, SUN Zhenxiao. Effectiveness of licorice and dried ginger decoction against mouse breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 88-92.
[7]	LIANG Feng, ZHANG Wei, LI Fei, WANG Shengjie, DU Yujing, ZHANG Yingchun. Expressions of lncRNA CASC9 in colorectal cancer and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 110-113.
[8]	GUO Xiaojuan, WANG Jinxi, NIU Guangxu, TIAN Yunxiao. Expression and correlation analyses of EGFR and HER-2 in different types of breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 119-123,148.
[9]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.
[10]	PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.
[11]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[12]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.
[13]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 435-441,460.
[14]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[15]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.